Related Experiment Video
Updated: Jun 29, 2025
10:01
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
6.5K
Local and Systemic Management Options for Melanoma Brain Metastases
Afsaneh Amouzegar1, Hussein A Tawbi
1From the Division of Cancer Medicine, Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Cancer Journal (Sudbury, Mass.)
|March 25, 2024
Summary
Melanoma brain metastases (MBMs) are a severe complication. Advances in local and systemic therapies offer hope, but MBM patients need inclusion in clinical trials for better treatment strategies.
Area of Science:
- Oncology
- Neurology
- Dermatology
Background:
- Melanoma brain metastases (MBMs) significantly increase morbidity and mortality in advanced melanoma patients.
- Management of MBMs is challenging due to historical exclusion from clinical trials, limiting treatment insights.
- Despite challenges, systemic therapies show promise for durable intracranial responses in MBM patients.
Approach:
- This review synthesizes current local and systemic treatment strategies for melanoma brain metastases.
- It emphasizes the need for increased clinical trial participation for MBM patients.
- The review highlights the evolving landscape of MBM management.
Key Points:
- Stereotactic radiosurgery and systemic therapies (immunotherapy, targeted therapy) have improved outcomes.
- MBMs present unique challenges not fully addressed by current trial designs.
- Evidence suggests systemic therapies can achieve lasting intracranial control.
Conclusions:
- Inclusion of MBM patients in clinical trials is crucial for developing tailored therapies.
- Advancing novel treatments for MBMs requires dedicated research and trial participation.
- Optimizing MBM management necessitates a focus on both local and systemic approaches.
